Uses of bispecific antibody coated dendritic cells pulsed with antigens and GM-CSF in immune regulation
View Patent ↗GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.
1. A composition comprising a semi-mature dendritic cell coated with a bispecific antibody, wherein the bispecific antibody binds to an antigenic surface molecule on a dendritic cell and to a T-cell receptor that suppresses T-cell activation.
2. The composition of claim 1 , wherein the inhibitory T cell receptor is CTLA-4.
3. The composition of claim 1 , wherein the dendritic cell is treated with GM-CSF to maintain semimature status.
4. The composition of claim 1 , wherein the dendritic cell is pulsed with an antigen of interest.
5. A bispecific anti-CTLA-4 antibody that activates CTLA-4 signaling to suppress T-cell activation, wherein the antibody binds to CTLA-4 and also to a specific molecule on a dendritic cell surface.
6. The composition of claim 1 , wherein the surface molecule is CD11 on dendritic cells.
7. The composition of claim 1 , wherein dendritic cells are pulsed with a tissue specific antigen.
8. The bispecific antibody of claim 5 , wherein the specific molecule on the dendritic cell is CD 11.